Eli Lilly

Healthcare

GLP-1 Race Heats Up with Positive Test Results for Next-Gen Eli Lilly Drug

Photo via Gado Images/Smith Collection/Gado/Sipa USA/Newscom

Approximately one in eight Americans are taking medications like Ozempic or Wegovy for weight loss, diabetes, heart disease and more.

2 min read

Photo via Michael Siluk/UCG/Universal Images Group/Newscom

Healthcare

Hims Teams up with Novo to Compete for Weight Loss Scripts

The two struck a deal Monday for Hims to offer official versions of Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy.

2 min read
Photo via Gado Images/Smith Collection/Gado/Sipa USA/Newscom

Healthcare

Eli Lilly Widens Access to Weight-Loss Injectable as Lower-Cost Pill Nears Approval

Just 20% of firms with 200 or more workers said they covered GLP-1 drugs for weight loss, according to the Peterson-KFF Health System Tracker.

2 min read
Photo via Ritzau Scanpix/Sipa USA/Newscom

Healthcare

Novo Nordisk Launches Suit to Knock Out Hims & Hers’ Weight Loss Knockoffs

Novo’s Copenhagen-listed shares rose 5.2% on Monday. New York-listed shares in Hims & Hers, meanwhile, shed an Ozempic-like 16% in volume.

2 min read

Healthcare

Treatment Advances Position Lilly as Weight-Loss Heavyweight

Photo by JHVEPhoto via iStock

The proliferation of cheaper generic drugs and more competition has already begun to bring down prices on weight-loss treatments.

2 min read

M&A

Novo Nordisk’s $10 Billion Bid Ups the Ante in Bidding War for Obesity Biotech Metsera

Photo via Mads Claus Rasmussen/ZUMAPRESS/Newscom

Metsera on Tuesday called Novo Nordisk’s new $10 billion offer “superior” to rival Pfizer’s bid of $8 billion.

2 min read

Healthcare

Eli Lilly Upstages Novo Nordisk in Obesity Pill Face-Off

Photo via James Black/Icon Sportswire DHN/James Black/Icon Sportswire/Newscom

Both companies have been desperate to innovate beyond their current injectable GLP-1 weight-loss drugs for a while now.

1 min read

Sign Up for The Daily Upside to Unlock This Article

Sharp news & analysis on finance, economics, and investing.